Citation

Papa L, Wang KK. J. Neurotrauma 2017; 34(13): 2187-2189.

Affiliation

University of Florida, Psychiatry , 1149 Newell Drive , L4-100 , Gainesville, Florida, United States , 32611 ; kawangwang17@gmail.com.

Copyright

(Copyright © 2017, Mary Ann Liebert Publishers)

DOI

10.1089/neu.2017.5030

PMID

28322619

Abstract

Research in blood-based traumatic brain injury (TBI) biomarkers has imploded over the last two decades and continues to grow at an unwavering pace. Commercialization of these biomarkers is ongoing, with a number of companies seeking FDA approval to market their test for clinical application. Although there are many papers being published, many lack the rigorous reporting required to adequately evaluate these markers for clinical use. Too often, there are inadequate sample sizes, inappropriate control groups and outcome measures, variable definitions of TBI, inconsistencies in when samples are drawn relative to time of injury, variability in how samples are processed and performance characteristics of the assays themselves are rarely known or poorly described. It is time to raise the bar on how we conduct blood-based TBI biomarker research and expect researchers, laboratories, and companies (producing and/or running assays) to perform at a higher standard.

Language: en

Keywords

BIOMARKERS; GUIDELINES; HEAD TRAUMA; HUMAN STUDIES; TRAUMATIC BRAIN INJURY